Early versus later response to treatment in patients with community-acquired pneumonia

Analysis of the REACH study

Francesco Blasi, Helmut Ostermann, Jill Racketa, Jesús Medina, Kyle McBride, Javier Garau

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Key goals in the treatment of CAP include early response to treatment and achievement of clinical stability. The US FDA recommends early response endpoints (72 hours after initiation of treatment) in clinical trials for the treatment of community-acquired bacterial pneumonia. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe Complicated Skin and Soft Tissue Infections [cSSTI] or CAP in the Hospital Setting) was a retrospective observational study, providing current data on the clinical management and resource burden of CAP in real-life settings in European hospitals. This analysis reviews the characteristics and outcomes of patients showing early positive response to treatment (time to clinical stability [TCS] ≤4 days, as assessed by Halm's criteria) compared with patients with later positive response (TCS >4 days).Methods: Patients were adults, hospitalized with CAP (2010-2011) and requiring in-hospital treatment with intravenous antibiotics.Results: Of the 2039 patients included in REACH, 585 (28.7%) had TCS assessed by Halm's criteria: 332 (56.8%) showed early response (median 3.0 days), and 253 (43.2%) showed later response to treatment (median 7.0 days). Use of Halm's criteria varied across participating countries, ranging from 0% (Belgium) to 49.1% (UK). Patient characteristics and relevant medical history were similar between the two groups. There were no notable differences in initial antibiotic therapy between groups, except that more early responders had been treated with amoxicillin-clavulanate and amoxicillin monotherapy (22.6%; 7.5%, respectively) than later responders (5.9%; 1.2%, respectively). Initial treatment modification and re-infection or recurrences were less frequent in early responders compared with later responders (14.2% and 3.3% vs. 34.8% and 5.9%, respectively). Early responders had a shorter duration of hospitalization (mean 9.4 ± SD 7.0; median 8.0 days vs. mean 15.6 ± SD 10.5; median 12.0 days, respectively), lower rate of ICU admission (3.3% vs. 21.3%) and shorter duration of ICU stay (mean 6.2 ± SD 5.7; median 4.0 days vs. mean 10.4 ± SD 10.1; median 8.0 days, respectively) compared with later responders. Mortality was low in both groups.Conclusions: Achieving early clinical stabilization in CAP (≤4 days) is associated with improved outcomes, lower requirement for initial treatment modification or readmission and lower resource use, compared with a later response.Trial registration: NCT01293435.

Original languageEnglish
Article number6
JournalRespiratory Research
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 22 2014

Fingerprint

Pneumonia
Therapeutics
Amoxicillin
Retrospective Studies
Anti-Bacterial Agents
Bacterial Pneumonia
Clavulanic Acid
Soft Tissue Infections
Belgium
Group Psychotherapy
Observational Studies
Hospitalization
Clinical Trials
Recurrence
Skin
Mortality
Infection

Keywords

  • Clinical stability
  • Community-acquired pneumonia
  • Early response
  • Resource use

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Early versus later response to treatment in patients with community-acquired pneumonia : Analysis of the REACH study. / Blasi, Francesco; Ostermann, Helmut; Racketa, Jill; Medina, Jesús; McBride, Kyle; Garau, Javier.

In: Respiratory Research, Vol. 15, No. 1, 6, 22.01.2014.

Research output: Contribution to journalArticle

Blasi, Francesco ; Ostermann, Helmut ; Racketa, Jill ; Medina, Jesús ; McBride, Kyle ; Garau, Javier. / Early versus later response to treatment in patients with community-acquired pneumonia : Analysis of the REACH study. In: Respiratory Research. 2014 ; Vol. 15, No. 1.
@article{0deb3df37e24438cb80f3d34b1112bd7,
title = "Early versus later response to treatment in patients with community-acquired pneumonia: Analysis of the REACH study",
abstract = "Background: Key goals in the treatment of CAP include early response to treatment and achievement of clinical stability. The US FDA recommends early response endpoints (72 hours after initiation of treatment) in clinical trials for the treatment of community-acquired bacterial pneumonia. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe Complicated Skin and Soft Tissue Infections [cSSTI] or CAP in the Hospital Setting) was a retrospective observational study, providing current data on the clinical management and resource burden of CAP in real-life settings in European hospitals. This analysis reviews the characteristics and outcomes of patients showing early positive response to treatment (time to clinical stability [TCS] ≤4 days, as assessed by Halm's criteria) compared with patients with later positive response (TCS >4 days).Methods: Patients were adults, hospitalized with CAP (2010-2011) and requiring in-hospital treatment with intravenous antibiotics.Results: Of the 2039 patients included in REACH, 585 (28.7{\%}) had TCS assessed by Halm's criteria: 332 (56.8{\%}) showed early response (median 3.0 days), and 253 (43.2{\%}) showed later response to treatment (median 7.0 days). Use of Halm's criteria varied across participating countries, ranging from 0{\%} (Belgium) to 49.1{\%} (UK). Patient characteristics and relevant medical history were similar between the two groups. There were no notable differences in initial antibiotic therapy between groups, except that more early responders had been treated with amoxicillin-clavulanate and amoxicillin monotherapy (22.6{\%}; 7.5{\%}, respectively) than later responders (5.9{\%}; 1.2{\%}, respectively). Initial treatment modification and re-infection or recurrences were less frequent in early responders compared with later responders (14.2{\%} and 3.3{\%} vs. 34.8{\%} and 5.9{\%}, respectively). Early responders had a shorter duration of hospitalization (mean 9.4 ± SD 7.0; median 8.0 days vs. mean 15.6 ± SD 10.5; median 12.0 days, respectively), lower rate of ICU admission (3.3{\%} vs. 21.3{\%}) and shorter duration of ICU stay (mean 6.2 ± SD 5.7; median 4.0 days vs. mean 10.4 ± SD 10.1; median 8.0 days, respectively) compared with later responders. Mortality was low in both groups.Conclusions: Achieving early clinical stabilization in CAP (≤4 days) is associated with improved outcomes, lower requirement for initial treatment modification or readmission and lower resource use, compared with a later response.Trial registration: NCT01293435.",
keywords = "Clinical stability, Community-acquired pneumonia, Early response, Resource use",
author = "Francesco Blasi and Helmut Ostermann and Jill Racketa and Jes{\'u}s Medina and Kyle McBride and Javier Garau",
year = "2014",
month = "1",
day = "22",
doi = "10.1186/1465-9921-15-6",
language = "English",
volume = "15",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Early versus later response to treatment in patients with community-acquired pneumonia

T2 - Analysis of the REACH study

AU - Blasi, Francesco

AU - Ostermann, Helmut

AU - Racketa, Jill

AU - Medina, Jesús

AU - McBride, Kyle

AU - Garau, Javier

PY - 2014/1/22

Y1 - 2014/1/22

N2 - Background: Key goals in the treatment of CAP include early response to treatment and achievement of clinical stability. The US FDA recommends early response endpoints (72 hours after initiation of treatment) in clinical trials for the treatment of community-acquired bacterial pneumonia. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe Complicated Skin and Soft Tissue Infections [cSSTI] or CAP in the Hospital Setting) was a retrospective observational study, providing current data on the clinical management and resource burden of CAP in real-life settings in European hospitals. This analysis reviews the characteristics and outcomes of patients showing early positive response to treatment (time to clinical stability [TCS] ≤4 days, as assessed by Halm's criteria) compared with patients with later positive response (TCS >4 days).Methods: Patients were adults, hospitalized with CAP (2010-2011) and requiring in-hospital treatment with intravenous antibiotics.Results: Of the 2039 patients included in REACH, 585 (28.7%) had TCS assessed by Halm's criteria: 332 (56.8%) showed early response (median 3.0 days), and 253 (43.2%) showed later response to treatment (median 7.0 days). Use of Halm's criteria varied across participating countries, ranging from 0% (Belgium) to 49.1% (UK). Patient characteristics and relevant medical history were similar between the two groups. There were no notable differences in initial antibiotic therapy between groups, except that more early responders had been treated with amoxicillin-clavulanate and amoxicillin monotherapy (22.6%; 7.5%, respectively) than later responders (5.9%; 1.2%, respectively). Initial treatment modification and re-infection or recurrences were less frequent in early responders compared with later responders (14.2% and 3.3% vs. 34.8% and 5.9%, respectively). Early responders had a shorter duration of hospitalization (mean 9.4 ± SD 7.0; median 8.0 days vs. mean 15.6 ± SD 10.5; median 12.0 days, respectively), lower rate of ICU admission (3.3% vs. 21.3%) and shorter duration of ICU stay (mean 6.2 ± SD 5.7; median 4.0 days vs. mean 10.4 ± SD 10.1; median 8.0 days, respectively) compared with later responders. Mortality was low in both groups.Conclusions: Achieving early clinical stabilization in CAP (≤4 days) is associated with improved outcomes, lower requirement for initial treatment modification or readmission and lower resource use, compared with a later response.Trial registration: NCT01293435.

AB - Background: Key goals in the treatment of CAP include early response to treatment and achievement of clinical stability. The US FDA recommends early response endpoints (72 hours after initiation of treatment) in clinical trials for the treatment of community-acquired bacterial pneumonia. REACH (REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe Complicated Skin and Soft Tissue Infections [cSSTI] or CAP in the Hospital Setting) was a retrospective observational study, providing current data on the clinical management and resource burden of CAP in real-life settings in European hospitals. This analysis reviews the characteristics and outcomes of patients showing early positive response to treatment (time to clinical stability [TCS] ≤4 days, as assessed by Halm's criteria) compared with patients with later positive response (TCS >4 days).Methods: Patients were adults, hospitalized with CAP (2010-2011) and requiring in-hospital treatment with intravenous antibiotics.Results: Of the 2039 patients included in REACH, 585 (28.7%) had TCS assessed by Halm's criteria: 332 (56.8%) showed early response (median 3.0 days), and 253 (43.2%) showed later response to treatment (median 7.0 days). Use of Halm's criteria varied across participating countries, ranging from 0% (Belgium) to 49.1% (UK). Patient characteristics and relevant medical history were similar between the two groups. There were no notable differences in initial antibiotic therapy between groups, except that more early responders had been treated with amoxicillin-clavulanate and amoxicillin monotherapy (22.6%; 7.5%, respectively) than later responders (5.9%; 1.2%, respectively). Initial treatment modification and re-infection or recurrences were less frequent in early responders compared with later responders (14.2% and 3.3% vs. 34.8% and 5.9%, respectively). Early responders had a shorter duration of hospitalization (mean 9.4 ± SD 7.0; median 8.0 days vs. mean 15.6 ± SD 10.5; median 12.0 days, respectively), lower rate of ICU admission (3.3% vs. 21.3%) and shorter duration of ICU stay (mean 6.2 ± SD 5.7; median 4.0 days vs. mean 10.4 ± SD 10.1; median 8.0 days, respectively) compared with later responders. Mortality was low in both groups.Conclusions: Achieving early clinical stabilization in CAP (≤4 days) is associated with improved outcomes, lower requirement for initial treatment modification or readmission and lower resource use, compared with a later response.Trial registration: NCT01293435.

KW - Clinical stability

KW - Community-acquired pneumonia

KW - Early response

KW - Resource use

UR - http://www.scopus.com/inward/record.url?scp=84892645128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892645128&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-15-6

DO - 10.1186/1465-9921-15-6

M3 - Article

VL - 15

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

IS - 1

M1 - 6

ER -